10-Q quarterly report · filed Oct 28, 2026

Replimune Group, Inc. (REPL) Q3 2026 10-Q Quarterly Report

Short answer

Replimune Group, Inc. (REPL) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$57M
+31.3% YoY · +18.1% QoQ
EPS (diluted)
−$0.54
+40.0% YoY · +25.0% QoQ

Source: XBRL data from the Replimune Group, Inc. (REPL) Q3 2026 10-Q on SEC EDGAR. USD.

Replimune Group, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales before TUDRIQEV commercialization in early October 2026
  • Operating margin not meaningful: operating loss $56.3M vs $84.3M YoY, net loss $57.1M vs $83.1M
  • Best program RP2: R&D spending $9.4M, up $4.2M YoY; worst RP1: $8.6M, down $9.0M
  • Operating cash outflow $123.4M; cash and equivalents plus short-term investments $307.8M at September 30, 2026
  • Outlook: cash sufficient for greater than twelve months; continued losses, commercialization and confirmatory-trial costs expectedETwitter

Risk Factors

  • New commercialization risk triggered by August 2026 FDA approval: rebuilding sales capabilities after significant reductions in force may delay TUDRIQEV launch
  • Most material regulatory update: accelerated approval depends on IGNYTE-3 confirmation, with FDA withdrawal possible if clinical benefit is unverified
  • Near-term market risk: TUDRIQEV remains the sole approved product, making revenue dependent on U.S. adoption in its melanoma indication
  • Financial risk: $307.8 million cash at September 30, 2026, but additional financing remains necessary and may be unavailable on acceptable terms
  • Manufacturing risk: approximately 63,000-square-foot Framingham facility may incur higher-than-expected costs or fail to achieve anticipated operating efficiencies

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Replimune Group, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.